Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Research Management Group

Neither a doctor nor a teaching hospital

Research payments

$769,953

28 payments

Through program year 2025, Clinical Research Management Group is reported as receiving $769,953 in research payments, across 28 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $82,535 15
2024 Research $102,015 4
2023 Research $72,719 4
2022 Research $512,684 5

Breakdown

Who paid Research payments · program years 2022–2025
  1. Pfizer Inc. $363,870 1 payment
  2. Eli Lilly Export S.A. Puerto Rico Branch $323,149 6 payments
  3. ConvaTec Inc. $80,005 16 payments
  4. Eli Lilly and Company $2,929 5 payments
Studies the money was for Research payments · program years 2022–2025
  1. Phase 11B Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients With Relapsed Andor Refractory Acute Myeloid Leukemia $363,870 1 payment
  2. A Phase 2 Study of Once-Daily Ly3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus $142,482 1 payment
  3. A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of Ly3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease $104,545 3 payments
  4. A Randomized Double-Blind Phase 3 Study to Investigate the Efficacy and Safety of Ly3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease $71,133 2 payments
  5. Innoven $69,175 14 payments
  6. INNOVEN: Efficacy of Porcine Placental Extracellular Matrix Plus Standard of Care (SOC) Versus SOC Alone $10,830 2 payments
  7. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease $6,332 3 payments
  8. A Phase 2 Study of Once-Daily Ly3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus $1,586 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record